Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Γαληνός Office Χρησιμοποιήστε δωρεάν το νέο cloud πρόγραμμα διαχείρισης κάθε σύγχρονου ιατρείου
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Πρόγραμμα συνδρομητών Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Γαληνός Mobile Κατεβάστε τη δωρεάν εφαρμογή και απολαύστε τις υπηρεσίες του Galinos.gr σε κινητό ή tablet
Γνωρίζατε οτι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα
®
 Φάρμακα Α - Ζ  Συγχορήγηση  Μητρότητα

DULCOLAX Gastro-resistant tablets (2017)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

DULCOLAX 5 mg Gastro-resistant Tablets.

Qualitative and quantitative composition

Each tablet contains Bisacodyl 5mg. For excipients, see 6.1.

Pharmaceutical form

Gastro-resistant tablets for oral administration. Circular, biconvex, yellow, sugar-coated and enteric-coated tablet.

Therapeutic indications

Short term relief of constipation.

Posology and method of administration

Adults and children over 10 years: 1 to 2 coated tablets (5-10 mg) daily before bedtime. It is recommended to start with the lowest dose. The dose may be adjusted up to the maximum recommended dose to ...

Contraindications

DULCOLAX is contraindicated in patients with ileus, intestinal obstruction, acute abdominal conditions including appendicitis, acute inflammatory bowel diseases, and severe abdominal pain associated with ...

Special warnings and precautions for use

As with all laxatives, DULCOLAX should not be taken on a continuous daily basis for more than five days without investigating the cause of constipation. Prolonged excessive use may lead to fluid and electrolyte ...

Interaction with other medicinal products and other forms of interaction

The concomitant use of antacids and milk products may reduce the resistance of the coating of the tablets and result in dyspepsia and gastric irritation. The concomitant use of diuretics or adreno-corticosteroids ...

Pregnancy and lactation

There are no adequate and well-controlled studies in pregnant women. Long experience has shown no evidence of undesirable or damaging effects during pregnancy. Clinical data show that neither the active ...

Effects on ability to drive and use machines

No studies on the effects of DULCOLAX on the ability to drive and use machines have been performed. However, patients should be advised that due to a vasovagal response (e.g. to abdominal spasm) they may ...

Undesirable effects

The most commonly reported adverse reactions during treatment are abdominal pain and diarrhoea. Adverse events have been ranked under headings of frequency using the following convention: Very common (≥1/10); ...

Overdose

Symptoms If high doses are taken watery stools (diarrhoea), abdominal cramps and a clinically significant loss of fluid, potassium and other electrolytes can occur. Laxatives when taken in chronic overdose ...

Pharmacodynamic properties

ATC code: A06AB02 Bisacodyl is a locally acting laxative from the diphenylmethane derivatives group having a dual action. As a contact laxative, for which also antiresorptive hydragogue effects have been ...

Pharmacokinetic properties

Following either oral or rectal administration, bisacodyl is rapidly hydrolyzed to the active principle bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), mainly by esterases of the enteric mucosa. Administration ...

Preclinical safety data

There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.

List of excipients

Tablet core: Lactose Maize starch Soluble maize starch Glycerol Magnesium stearate Tablet coating: Magnesium stearate Sucrose Talc Acacia Titanium dioxide (E171) Methacrylic acid-methylmethacrylate copolymer ...

Incompatibilities

None stated.

Shelf life

Shelf life: 3 years.

Special precautions for storage

Do not store above 25°C. Keep container in the outer carton.

Nature and contents of container

Blister packs consisting of opaque white PVC/PVDC blister foil and aluminium foil (covering foil). Blister packs consisting of colourless PVC blister foil and aluminium foil (covering foil). Packs of 6, ...

Special precautions for disposal and other handling

None stated.

Marketing authorization holder

Aventis Pharma Limited, One Onslow Street, Guildford, Surrey, GU1 4YS, United Kingdom Trading as: Sanofi, One Onslow Street, Guildford, Surrey, GU1 4YS, United Kingdom

Marketing authorization number(s)

PL 04425/0718

Date of first authorization / renewal of the authorization

01 June 1992 / 25 February 2005

Date of revision of the text

December 2017

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: